CA2354057A1 - Sustained release tablet containing hydrocolloid and cellulose ether - Google Patents
Sustained release tablet containing hydrocolloid and cellulose ether Download PDFInfo
- Publication number
- CA2354057A1 CA2354057A1 CA002354057A CA2354057A CA2354057A1 CA 2354057 A1 CA2354057 A1 CA 2354057A1 CA 002354057 A CA002354057 A CA 002354057A CA 2354057 A CA2354057 A CA 2354057A CA 2354057 A1 CA2354057 A1 CA 2354057A1
- Authority
- CA
- Canada
- Prior art keywords
- cellulose ether
- present
- sustained release
- tablet
- hydrocolloid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Abstract
The present invention is directed to a solid sustained release pharmaceutical tablet for administering to a host, comprising a therapeutically effective amount of a pharmaceutically active ingredient and a sustained release carrier therefor, said sustained release carrier comprising (a) a hydrocolloid selected from the group consisting of xanthan gum, guar gum, and alginic acid or a pharmaceutically acceptable salt thereof, and (b) a cellulose ether, said hydrocolloid and cellulose ether being present in synergistic effective amount to retard release of said pharmaceutically active ingredient, said hydrocolloid being present in amount ranging from about 0.3 % to about 7.0 % by weight of the tablet and said cellulose ether being present in an amount ranging from 3 % to about 20 % of said tablet, and cellulose ether being present in said carrier in amounts equal to or greater than 33 % by weight and said carrier being present in amounts less than 35 % by weight of said tablet.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11196498P | 1998-12-11 | 1998-12-11 | |
US60/111,964 | 1998-12-11 | ||
PCT/US1999/029372 WO2000033818A1 (en) | 1998-12-11 | 1999-12-10 | Sustained release tablet containing hydrocolloid and cellulose ether |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2354057A1 true CA2354057A1 (en) | 2000-06-15 |
CA2354057C CA2354057C (en) | 2009-02-10 |
Family
ID=22341399
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002354057A Expired - Fee Related CA2354057C (en) | 1998-12-11 | 1999-12-10 | Sustained release tablet containing hydrocolloid and cellulose ether |
Country Status (9)
Country | Link |
---|---|
US (1) | US6416786B1 (en) |
EP (1) | EP1137403B1 (en) |
JP (1) | JP2002531491A (en) |
AT (1) | ATE424810T1 (en) |
AU (1) | AU772891B2 (en) |
CA (1) | CA2354057C (en) |
DE (1) | DE69940557D1 (en) |
NZ (1) | NZ512288A (en) |
WO (1) | WO2000033818A1 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19933289A1 (en) * | 1999-07-15 | 2001-01-18 | Basf Ag | Process for the production of granules from a melt |
US7985420B2 (en) | 2000-04-28 | 2011-07-26 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
US8012504B2 (en) | 2000-04-28 | 2011-09-06 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
US6955821B2 (en) | 2000-04-28 | 2005-10-18 | Adams Laboratories, Inc. | Sustained release formulations of guaifenesin and additional drug ingredients |
US7838032B2 (en) | 2000-04-28 | 2010-11-23 | Reckitt Benckiser Inc. | Sustained release of guaifenesin |
WO2002085335A1 (en) * | 2001-04-18 | 2002-10-31 | Nostrum Pharmaceuticals Inc. | A novel coating for a sustained release pharmaceutical composition |
US20020198209A1 (en) | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Compositions having enhanced pharmacokinetic characteristics |
CN1655766B (en) * | 2002-04-15 | 2012-05-30 | 利洁时有限责任公司 | Sustained release of guaifenesin combination drugs |
KR100548925B1 (en) * | 2002-10-23 | 2006-02-02 | 한미약품 주식회사 | Sustained release composition for oral administration of a drug |
WO2004041202A2 (en) * | 2002-11-04 | 2004-05-21 | Transform Pharmaceuticals, Inc. | Analysis of pharmaceutical solubility and stability |
EP1603540A2 (en) * | 2003-03-14 | 2005-12-14 | Nirmal Mulye | A process for preparing sustained release tablets |
US20060177497A1 (en) * | 2003-07-21 | 2006-08-10 | Bio Dar Ltd. | Gellan gum based oral controlled release dosage forms-a novel platform technology for gastric retention |
US7163101B2 (en) * | 2003-10-30 | 2007-01-16 | William Anthony Harper | Flexible liquid packet with rigid insert |
FR2861990B1 (en) * | 2003-11-10 | 2006-02-10 | Nouveaux Produits Pharma | LOW DOSAGE TABLETS WITH POLYMER NETWORK |
US20050202079A1 (en) * | 2004-03-15 | 2005-09-15 | Mylan Pharmaceuticals Inc. | Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation |
KR101366764B1 (en) * | 2005-05-31 | 2014-02-25 | 주식회사 씨티씨바이오 | Manufacturing method of controlled-release tablet containing doxazocin mesylate |
US20070141147A1 (en) * | 2005-12-21 | 2007-06-21 | Auriga Laboratories, Inc. | Sequential release pharmaceutical formulations |
CA2569776A1 (en) * | 2006-02-17 | 2007-08-17 | Kos Life Sciences, Inc. | Low flush niacin formulation |
US20080064694A1 (en) * | 2006-09-11 | 2008-03-13 | Auriga Laboratories, Inc. | Multi-Phase Release Methscopolamine Compositions |
US20080069874A1 (en) * | 2006-09-15 | 2008-03-20 | Auriga Laboratories, Inc. | Kits for Prevention and Treatment of Rhinitis |
US20080085312A1 (en) * | 2006-10-04 | 2008-04-10 | Auriga Laboratories, Inc. | Multi-Phase Release Potassium Guaiacolsulfonate Compositions |
KR100836960B1 (en) * | 2007-09-07 | 2008-06-10 | 주식회사 서울제약 | A novel controlled release-niacin formulation |
US20090202633A1 (en) * | 2008-01-03 | 2009-08-13 | Siva Ramakrishna Velaga | Extended release formulations of guaifenesin |
CN103190631B (en) * | 2008-03-20 | 2016-01-20 | 维尔恩公司 | Non-aqueous pre-emulsion composition and preparation comprise the method for the beverage of phytosterol |
EP2268160B1 (en) | 2008-03-20 | 2012-12-05 | Virun, Inc. | Emulsions including a peg-derivative of tocopherol |
US20100160363A1 (en) * | 2008-12-19 | 2010-06-24 | Aaipharma Services Corp. | Extended-release pharmaceutical formulations |
US20100159001A1 (en) * | 2008-12-19 | 2010-06-24 | Cardinal John R | Extended-Release Pharmaceutical Formulations |
CN103037708B (en) * | 2010-03-23 | 2015-05-20 | 维尔恩公司 | Nanoemulsion including sucrose fatty acid ester |
US9351517B2 (en) | 2013-03-15 | 2016-05-31 | Virun, Inc. | Formulations of water-soluble derivatives of vitamin E and compositions containing same |
WO2017062997A1 (en) | 2015-10-09 | 2017-04-13 | Reckitt Benckiser Llc | Pharmaceutical formulation |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
US4795327A (en) | 1984-03-26 | 1989-01-03 | Forest Laboratories, Inc. | Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants |
JPS6124516A (en) | 1984-07-12 | 1986-02-03 | Fujisawa Pharmaceut Co Ltd | Long active tablet |
US4610870A (en) * | 1984-10-05 | 1986-09-09 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
JPH0830005B2 (en) | 1985-09-25 | 1996-03-27 | ゲルゲリイ、ゲルハルト | Disintegrating tablet and manufacturing method thereof |
US4734285A (en) | 1985-10-28 | 1988-03-29 | The Dow Chemical Company | Sustained release compositions |
US4704285A (en) | 1985-11-18 | 1987-11-03 | The Dow Chemical Company | Sustained release compositions comprising hydroxypropyl cellulose ethers |
GB8601204D0 (en) | 1986-01-18 | 1986-02-19 | Boots Co Plc | Therapeutic agents |
GB2186485B (en) | 1986-02-13 | 1988-09-07 | Ethical Pharma Ltd | Slow release formulation |
IT1191674B (en) * | 1986-03-07 | 1988-03-23 | Eurand Spa | FORMULATIONS FOR THE PREPARATION OF PROLONGED-RELEASE DRUGS SUITABLE FOR ORAL ADMINISTRATION |
US4775535A (en) | 1986-04-04 | 1988-10-04 | Hans Lowey | Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics |
US4855143A (en) | 1986-04-04 | 1989-08-08 | Hans Lowey | Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics |
US4752479A (en) | 1986-05-27 | 1988-06-21 | Ciba-Geigy Corporaton | Multi vitamin and mineral dietary supplement with controlled release bioavailable iron |
GB8713169D0 (en) | 1987-06-05 | 1987-07-08 | Peters T J | Uptake of iron by body |
GB8702411D0 (en) | 1987-02-03 | 1987-03-11 | Zyma Sa | Swellable pellets |
US4786518A (en) | 1987-07-02 | 1988-11-22 | The Procter & Gamble Company | Iron mineral supplements |
US4792452A (en) * | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
US4994276A (en) | 1988-09-19 | 1991-02-19 | Edward Mendell Co., Inc. | Directly compressible sustained release excipient |
IE60311B1 (en) | 1987-09-24 | 1994-06-29 | American Home Prod | Sustained release etodolac |
SE8703881D0 (en) * | 1987-10-08 | 1987-10-08 | Haessle Ab | NEW PHARMACEUTICAL PREPARATION |
DE3809625A1 (en) | 1988-03-22 | 1989-10-05 | Verla Pharm | ORAL-AVAILABLE PHARMACEUTICAL AGENT, IN PARTICULAR FOR IRON AND MAGNESIUM SUBSTITUTION THERAPY |
US5006346A (en) | 1988-04-28 | 1991-04-09 | Alza Corporation | Delivery system |
US5135757A (en) | 1988-09-19 | 1992-08-04 | Edward Mendell Co., Inc. | Compressible sustained release solid dosage forms |
US5128143A (en) | 1988-09-19 | 1992-07-07 | Edward Mendell Co., Inc. | Sustained release excipient and tablet formulation |
US5169639A (en) * | 1988-09-19 | 1992-12-08 | Edward Mendell Co., Inc. | Controlled release verapamil tablets |
US5126145A (en) | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
US5002774A (en) | 1989-06-08 | 1991-03-26 | Erbamont, Inc. | Sustained release pharmaceutical tablet |
US4973470A (en) | 1989-06-26 | 1990-11-27 | Warner-Lambert Company | Sustained release pharmaceutical compositions |
US5077051A (en) | 1990-04-10 | 1991-12-31 | Warner-Lambert Company | Sustained release of active agents from bioadhesive microcapsules |
JPH0482826A (en) * | 1990-07-26 | 1992-03-16 | Shin Etsu Chem Co Ltd | Sustained releasing tablet |
JPH0794379B2 (en) | 1990-08-07 | 1995-10-11 | ファイザー・インコーポレーテッド | Methods of using interfacial polymerized membranes in release formulations |
US5204116A (en) | 1991-05-01 | 1993-04-20 | Alza Corporation | Dosage form providing immediate therapy followed by prolonged therapy |
US5223268A (en) | 1991-05-16 | 1993-06-29 | Sterling Drug, Inc. | Low solubility drug-coated bead compositions |
IT1251153B (en) * | 1991-08-06 | 1995-05-04 | Vectorpharma Int | SOLID PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION HAVING PROHIBITED GASTRIC RESIDENCE |
JP2669446B2 (en) | 1992-03-23 | 1997-10-27 | 信越化学工業株式会社 | Raw material powder for pharmaceutical coating liquid |
US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
US5292534A (en) | 1992-03-25 | 1994-03-08 | Valentine Enterprises, Inc. | Sustained release composition and method utilizing xanthan gum and an active ingredient |
US5472711A (en) | 1992-07-30 | 1995-12-05 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
SE9301220D0 (en) | 1993-04-14 | 1993-04-14 | Kabi Pharmacia Ab | MANUFACTURING MATRICES |
IT1264696B1 (en) | 1993-07-09 | 1996-10-04 | Applied Pharma Res | PHARMACEUTICAL FORMS INTENDED FOR ORAL ADMINISTRATION ABLE TO RELEASE ACTIVE SUBSTANCES AT A CONTROLLED AND DIFFERENTIATED SPEED |
US5773025A (en) | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
US5455046A (en) | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US5662933A (en) | 1993-09-09 | 1997-09-02 | Edward Mendell Co., Inc. | Controlled release formulation (albuterol) |
HU213407B (en) | 1993-12-09 | 1997-06-30 | Egyt Gyogyszervegyeszeti Gyar | Process for producing tablet with diffusive-osmotic release |
US5419917A (en) | 1994-02-14 | 1995-05-30 | Andrx Pharmaceuticals, Inc. | Controlled release hydrogel formulation |
DE19509807A1 (en) | 1995-03-21 | 1996-09-26 | Basf Ag | Process for the preparation of active substance preparations in the form of a solid solution of the active substance in a polymer matrix, and active substance preparations produced using this method |
US5464633A (en) | 1994-05-24 | 1995-11-07 | Jagotec Ag | Pharmaceutical tablets releasing the active substance after a definite period of time |
US5700832A (en) | 1994-10-19 | 1997-12-23 | Daewon Pharm. Co., Ltd. | Antianemic agent containing iron and difructose |
IL139728A (en) | 1995-01-09 | 2003-06-24 | Penwest Pharmaceuticals Compan | Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient |
US5612053A (en) | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
US5811126A (en) | 1995-10-02 | 1998-09-22 | Euro-Celtique, S.A. | Controlled release matrix for pharmaceuticals |
IT1282650B1 (en) | 1996-02-19 | 1998-03-31 | Jagotec Ag | PHARMACEUTICAL TABLET, CHARACTERIZED BY A HIGH INCREASE IN VOLUME IN CONTACT WITH BIOLOGICAL LIQUIDS |
CA2173818A1 (en) | 1996-04-10 | 1997-10-11 | Francois Chouinard | Time-released pharmaceutical compound containing a cured amylose-based support and hydroxypropylmethylcellulose |
US5895663A (en) | 1997-07-31 | 1999-04-20 | L. Perrigo Company | Pseudoephedrine hydrochloride extended-release tablets |
US5851555A (en) | 1997-08-15 | 1998-12-22 | Fuisz Technologies Ltd. | Controlled release dosage forms containing water soluble drugs |
-
1999
- 1999-12-10 AT AT99968872T patent/ATE424810T1/en not_active IP Right Cessation
- 1999-12-10 CA CA002354057A patent/CA2354057C/en not_active Expired - Fee Related
- 1999-12-10 AU AU27079/00A patent/AU772891B2/en not_active Ceased
- 1999-12-10 US US09/459,300 patent/US6416786B1/en not_active Expired - Lifetime
- 1999-12-10 NZ NZ512288A patent/NZ512288A/en not_active IP Right Cessation
- 1999-12-10 WO PCT/US1999/029372 patent/WO2000033818A1/en active IP Right Grant
- 1999-12-10 EP EP99968872A patent/EP1137403B1/en not_active Expired - Lifetime
- 1999-12-10 DE DE69940557T patent/DE69940557D1/en not_active Expired - Lifetime
- 1999-12-10 JP JP2000586311A patent/JP2002531491A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2707900A (en) | 2000-06-26 |
ATE424810T1 (en) | 2009-03-15 |
NZ512288A (en) | 2003-09-26 |
WO2000033818A9 (en) | 2001-02-01 |
DE69940557D1 (en) | 2009-04-23 |
EP1137403B1 (en) | 2009-03-11 |
EP1137403A1 (en) | 2001-10-04 |
JP2002531491A (en) | 2002-09-24 |
CA2354057C (en) | 2009-02-10 |
US6416786B1 (en) | 2002-07-09 |
EP1137403A4 (en) | 2005-10-26 |
WO2000033818A1 (en) | 2000-06-15 |
AU772891B2 (en) | 2004-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2354057A1 (en) | Sustained release tablet containing hydrocolloid and cellulose ether | |
HUP0004383A2 (en) | Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient | |
AU7451198A (en) | Solid pharmaceutical preparation | |
CA2258095A1 (en) | Tetrahydrolipstatin containing compositions | |
TW376319B (en) | Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine | |
WO1996007398A3 (en) | Sustained release of peptides from pharmaceutical compositions | |
KR950007841A (en) | Sustained-release drug formulations containing tramadol salts | |
CA2126611A1 (en) | Opiod Formulations Having Extended Controlled Release | |
MY125662A (en) | Pharmaceutical formulations containing darifenacin | |
GEP20033131B (en) | Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity | |
IE894048L (en) | New therapeutically active compound and a process for its¹preparation | |
AU1557595A (en) | Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents | |
ES2110212T3 (en) | EFFERVESCENT PHARMACEUTICAL COMPOSITION CONTAINING IBUPROPHEN AND ITS PREPARATION PROCEDURE. | |
CA2294913A1 (en) | Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxamic acid derivative | |
AU764280C (en) | Process for the preparation of pellets with a content of up to 90 wt. per cent of a pharmaceutical active ingredient | |
CA2330480A1 (en) | Controlled release formulation of divalproex sodium | |
JP2002524415A5 (en) | ||
GR1003658B (en) | Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route | |
CA2136404A1 (en) | Mucoadhesive, therapeutic or hygienic solid composition for application on oral or nasal mucosa | |
JP2000159790A5 (en) | ||
HK1023508A1 (en) | Stabilized tibolone compositions. | |
HUT70531A (en) | Arylmorpholine derivatives, pharmaceutical compositions containing them as active agent and process for preparing them | |
HUP9903410A2 (en) | Rapid release tablet comprising tolfenamic acid or a pharmaceutically acceptable salt thereof | |
SI9620036B (en) | Aminotetralin derivative for the therapy of cardiovascular diseases | |
AU1039400A (en) | Opioid analgesic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed | ||
MKLA | Lapsed |
Effective date: 20111212 |